New Diabetes Pill Offers Fat-Burning Benefits Without Muscle Loss
Researchers at Karolinska Institutet and Stockholm University have developed a new pill that could revolutionize the treatment of type 2 diabetes and obesity. Unlike current GLP-1 medications such as Ozempic, which are administered via injection and work by suppressing appetite, this new treatment targets metabolism within skeletal muscle. The drug, a β2 agonist, is designed to activate signaling pathways that enhance muscle metabolism without overstimulating the heart. Early trials have shown that the pill can improve blood sugar regulation and body composition without the side effects commonly associated with GLP-1 therapies, such as appetite suppression and muscle loss. Initial human trials involving 48 healthy volunteers and 25 individuals with type 2 diabetes have shown promising results, with participants tolerating the treatment well. 
